C4 Therapeutics, Inc.

CCCC

$3.71

-3.64%

2026-08-31 16:00:01 EDT-$0.14

Healthcare

Biotechnology

NASDAQ

Active Trading

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins ...

Price Action of CCCC

$3.71

-3.64%-$0.14

High—

Low—

52W High-28.2%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

C4 Therapeutics, Inc. (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, founded in 2015. The company specializes in targeted protein degradation (TPD), a revolutionary approach to drug discovery that leverages the body's own cellular machinery to selectively eliminate disease-causing proteins. C4T's proprietary TORPEDO platform enables the design ...C4 Therapeutics, Inc. (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, founded in 2015. The company specializes in targeted protein degradation (TPD), a revolutionary approach to drug discovery that leverages the body's own cellular machinery to selectively eliminate disease-causing proteins. C4T's proprietary TORPEDO platform enables the design of small molecules that can degrade proteins of interest, offering potential advantages over traditional inhibitors, including the ability to target previously 'undruggable' proteins and overcome resistance mechanisms. C4T's lead product candidate, CFT7455, is an orally administered MonoDAC degrader targeting IKZF1 and IKZF3, currently in Phase 1/2 clinical trials for multiple myeloma and non-Hodgkin lymphomas. Additional pipeline assets include CFT8634 (BRD9 degrader for synovial sarcoma and SMARCB1-deleted tumors), CFT1946 (mutant BRAF V600X degrader for melanoma and other solid tumors), and CFT8919 (EGFR L858R degrader for non-small cell lung cancer). Early-stage programs include RET degraders for various cancers. The company has established strategic partnerships with major pharmaceutical companies, including Roche, Biogen, and Calico Life Sciences, to expand its research and development capabilities. Financially, C4T is a growth-stage company with no approved products, generating revenue primarily from collaborations. As of recent data, the company has a market capitalization of approximately $412 million, with a focus on advancing its pipeline through clinical trials. Key leadership includes CEO Andrew Hirsch, who joined in 2020, and the company's co-founders include Jay Bradner, Ken Anderson, and Marc Cohen (who passed away in 2022). C4T employs around 104 full-time staff and continues to invest heavily in R&D to bring innovative therapies to patients.ExpandCollapse

Founded

2015

Employees

104

CEO

Andrew J. Hirsch

Full Name

C4 Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-45.45%

Market Cap

$0.41B

Current Ratio

5.45

WACC

16.17%

ROIC

-39.55%

Contact Information

https://www.c4therapeutics.com

617 231 0700

490 Arsenal Way, Watertown, MA 02472

Key Metrics of CCCC

Snapshot

Latest / TTM · 6 periods

Market Cap

$410.20M

ROCE

-35.9%

EV / EBITDA

-3.98x

-3.9% YoY

FCF Yield

-20.7%

+42.1% YoY

Cash Conversion Cycle

-213.3d

Current Ratio

5.45

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of CCCC

Profitability trend

Latest / TTM · 6 periods

Gross Margin

94.9%

Net Margin

-289.4%

P/E Ratio

-3.74x

n/a

Debt / Equity

0.23

n/a

Current Ratio

5.45

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of CCCC

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.20 · Revenue $8.82M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.29 · Revenue $4.00M · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.87 · Revenue $25.66M · 4 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.27 · Revenue $5.00M · 1 analysts

Recent history

Aug 11, 2026
Q2 FY2026 · Results reported
EPS $-0.18 · Revenue $6.64M
View filing
May 12, 2026
Q1 FY2026 · Results reported
EPS $-0.20 · Revenue $6.15M
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $-1.27 · Revenue $35.95M
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-0.44 · Revenue $11.23M
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-0.37 · Revenue $6.46M
View filing
May 7, 2025
Q1 FY2025 · Results reported
EPS $-0.37 · Revenue $7.24M
View filing

Financial Statements of CCCC

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$35.9M	+1.0%	+7.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-105.0M	+0.3%	+5.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+77.8%	-22.2%	+41.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-290.7%	+13.5%	+11.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-292.1%	+1.3%	+12.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-99.3M	-52.0%	+94.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-276.2%	-50.4%	+95.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	23.4%	-23.2%	-7.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	7.81x	+36.9%	-39.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$359.1M	+2.7%	+9.3%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.27 vs -1.41	+9.7%	-0.18 vs -0.23	+20.5%
Revenue Surprise	$35.9M vs $30.4M	+18.4%	$6.6M vs $4.0M	+66.0%

Insider Transactions of CCCC

Acquisitions (A)

Since Jun 24, 2026

Disposals (D)

Since Jun 24, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 10, 2026	REYNO LEONARD	officer: Chief Medical Officer	Common Stock	A	15,325	—
Jul 10, 2026	REYNO LEONARD	officer: Chief Medical Officer	Common Stock	D	7,397	$4.06
Jul 1, 2026	Anderson Kenneth Carl	director	Common Stock	A	2,650	$4.34
Jul 1, 2026	GROGAN DONNA ROY	director	Common Stock	A	3,341	$4.34
Jun 24, 2026	Hughes Owen	director	Stock Option (Right to Buy)	A	62,000	$4.25

Leadership Team of CCCC

11 executives

Name	Title	Compensation	Gender	Year Born	Status
Andrew J. Hirsch	Chief Executive Officer, President & Director	USD 1,382,238	Male	1971	Active
Leonard J. Reyno	Chief Medical Officer	USD 1,034,520	—	1962	Active
Kendra Adams	Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer	USD 869,511	Female	1977	Active
Paige Mahaney	Chief Scientific Officer	USD 657,342	Female	1970	Active
Kenneth C. Anderson	Co-Founder, Independent Director & Member of Scientific Advisory Board	USD 45,750	—	1951	Active
Roy Pollock	Senior Vice President of Biological Sciences	—	Male	—	Active
Courtney Solberg	Senior Manager of Investor Relations	—	Female	—	Active
Kelly Schick	Chief People Officer	—	Female	1980	Active
Nathanael S. Gray	Co-Founder & Member of Scientific Advisory Board	—	—	—	Active
Christopher Nasveschuk	Senior Vice President of Chemistry	—	—	—	Active
Isabel Chiu	Senior Vice President of Strategic Alliances & Business Development	—	—	—	Active

Recent News of CCCC

Zacks Investment Research8/21/2026Neutral

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research8/11/2026Neutral

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.37 per share a year ago.

Zacks Investment Research7/7/2026Neutral

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.

Zacks Investment Research7/3/2026Neutral

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Seeking Alpha6/18/2026Neutral

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript

Historical Employee Count of CCCC

Current

104

Change

-5.45%

Minimum

104

Maximum

146

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	104	10-K	Feb 26, 2026	View
Dec 31, 2024	110	10-K	Feb 27, 2025	View
Dec 31, 2023	145	10-K	Feb 22, 2024	View
Dec 31, 2022	146	10-K	Feb 23, 2023	View
Dec 31, 2021	121	10-K	Feb 24, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

C4 Therapeutics, Inc.